Mineral bone disorder and its management among hemodialysis patients in the Gulf Cooperation Council: Initial findings from the dialysis outcomes and practice patterns study (2012-2015)
Abstract:The prospective cohort Dialysis Outcomes and Practice Patterns Study (DOPPS) initiated data collection in national samples of hemodialysis (HD) units (total of 41 study sites) in all six Gulf Cooperation Council (GCC) countries (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates) in late 2012. Here, we report initial results regarding mineral bone disorders (MBDs) and its management in the GCC countries. Forty-one randomly selected HD facilities, treating >23 HD patients each, were sample… Show more
“…Patients below the upper limit )300 pg/ml( were 23.8% )n=67(; this upper limit was reported by 71% of the centers enrolled in the DOPPS involving GCC. 9 Our sample showed a high level of parathyroid hormone )64% [n=152]( consistent with the DOPPS study, which reported high median parathyroid level in Saudi Arabia )523 pg/ml( compared to the GCC average )452 pg/ml( this results are considered higher than results in Japan and Europe. Out of patients below upper limit, 4.8% )n=13( of patients showed levels of parathyroid hormone that considered as low bone turnover and required further assessment and treatment.…”
Section: Discussionsupporting
confidence: 89%
“…Thus, the control of serum phosphorus is considered a critical factor in improving the clinical outcomes in CKD-MBD, including survival. 8 , 9 Moreover, hyperphosphatemia represents a significant cause of morbidity and mortality in hemodialysis patients, as phosphate is not effectively removed by dialysis, the patients are required to follow a protein-restricted diet to decrease phosphate consumption. 10 Oral phosphate binders are required by the majority of patients on hemodialysis, which are agents used to control serum phosphate levels through different action mechanisms, but the net result is to prevent gastrointestinal phosphate absorption.…”
To assess phosphate binders' usage, knowledge regarding their utilization, and adherence among hemodialysis patients in Qassim, Saudi Arabia. Methods: A prospective cross-sectional study conducted at 4 dialysis centers in Qassim, Saudi Arabia with inclusion of 237 patients' undergoing hemodialysis between November 2018 to January 2019. The study involved interviewing the patients, reviewing their Original Article medical records for biomarkers used to assess kidney function, and assessing the patients' knowledge-based regarding dietary phosphate control, as well as adherence to phosphate binders' usage. Results: Out of 237 included patients, male to female ratio was 54:46. The prevalence of prescribing noncalcium phosphate binders was 82.7% whereas prescribing calcium phosphate binders was 73.8%. A total of 63% of patients showed a medium level of adherence to phosphate binders. Although adherence level was not poor, therapeutic efficacy was affected by other factors such as administration time adherence positively correlated with the serum phosphate level)p=0.00(. Conclusion: Phosphate binders usage is frequent among hemodialysis patients in Qassim centers. Circulating phosphate level was affected by the extent of patients' knowledge of dietary control and adherence to the usage of phosphate binders. Thus, we recommend enhancing patient education in reference to high-and lowphosphate-rich diet to take wise dietary decisions, lower pill burden, and improve adherence toward the control of hyperphosphatemia
“…Patients below the upper limit )300 pg/ml( were 23.8% )n=67(; this upper limit was reported by 71% of the centers enrolled in the DOPPS involving GCC. 9 Our sample showed a high level of parathyroid hormone )64% [n=152]( consistent with the DOPPS study, which reported high median parathyroid level in Saudi Arabia )523 pg/ml( compared to the GCC average )452 pg/ml( this results are considered higher than results in Japan and Europe. Out of patients below upper limit, 4.8% )n=13( of patients showed levels of parathyroid hormone that considered as low bone turnover and required further assessment and treatment.…”
Section: Discussionsupporting
confidence: 89%
“…Thus, the control of serum phosphorus is considered a critical factor in improving the clinical outcomes in CKD-MBD, including survival. 8 , 9 Moreover, hyperphosphatemia represents a significant cause of morbidity and mortality in hemodialysis patients, as phosphate is not effectively removed by dialysis, the patients are required to follow a protein-restricted diet to decrease phosphate consumption. 10 Oral phosphate binders are required by the majority of patients on hemodialysis, which are agents used to control serum phosphate levels through different action mechanisms, but the net result is to prevent gastrointestinal phosphate absorption.…”
To assess phosphate binders' usage, knowledge regarding their utilization, and adherence among hemodialysis patients in Qassim, Saudi Arabia. Methods: A prospective cross-sectional study conducted at 4 dialysis centers in Qassim, Saudi Arabia with inclusion of 237 patients' undergoing hemodialysis between November 2018 to January 2019. The study involved interviewing the patients, reviewing their Original Article medical records for biomarkers used to assess kidney function, and assessing the patients' knowledge-based regarding dietary phosphate control, as well as adherence to phosphate binders' usage. Results: Out of 237 included patients, male to female ratio was 54:46. The prevalence of prescribing noncalcium phosphate binders was 82.7% whereas prescribing calcium phosphate binders was 73.8%. A total of 63% of patients showed a medium level of adherence to phosphate binders. Although adherence level was not poor, therapeutic efficacy was affected by other factors such as administration time adherence positively correlated with the serum phosphate level)p=0.00(. Conclusion: Phosphate binders usage is frequent among hemodialysis patients in Qassim centers. Circulating phosphate level was affected by the extent of patients' knowledge of dietary control and adherence to the usage of phosphate binders. Thus, we recommend enhancing patient education in reference to high-and lowphosphate-rich diet to take wise dietary decisions, lower pill burden, and improve adherence toward the control of hyperphosphatemia
“…The analysis described here includes data collected in the initial prevalent cross-section of patients enrolled in DOPPS phase 5 from 2012 to 2015 in 20,612 patients in 543 facilities across Europe (Belgium, France, Germany, Italy, Spain, Sweden, and the UK), Russia, Asia (China and Japan), Saudi Arabia (results for additional GCC countries have been published separately [23]), and North America (Canada and the USA). Specific parameters analyzed to assess the management of SHPT included biochemical measures and the use of SHPT medications.…”
Section: Study Design Patients and Data Collectionmentioning
confidence: 99%
“…More recently, using DOPPS phase 1–4 data (1996–2011), an iPTH elevation to > 600 pg/mL (HR 1.23) and even milder elevation of iPTH (301–450 pg/mL) were associated with mortality compared with the reference range of 150–300 pg/mL (HR 1.09) [ 22 ]. Initial findings from DOPPS phase 5 (2012–2015) in Russia and countries of the Middle East that are part of the Gulf Cooperation Council (GCC; Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and United Arab Emirates) have demonstrated variation in practices and opportunities for improvement of care [ 23 , 24 ].…”
Introduction: This analysis explored laboratory mineral and bone disorder parameters and management of secondary hyperparathyroidism in patients undergoing hemodialysis in Belgium,
“…We were able to reveal patient characteristics on all study parameters. While existing studies in the region are limited to their descriptive and cross-sectional nature [28,29], or to their short intervention time [30], the current study is unique in its prospective interventional design implementing the IDE program in UAE.…”
Aim. Intradialytic exercise (IDE) improves hyperphosphatemia management in hemodialysis (HD) patient in addition to other clinical outcomes. The aim of the study is to present the strategies needed to integrate such a protocol in an HD unit in UAE and patients' baseline characteristics. Methods. The largest HD unit in Sharjah emirate was chosen. All eligible patients (n = 57) in the unit were included. Patients were stable adults HD patients who served as their own controls. The intervention included an aerobic low intensity IDE of 45 minutes per HD session, tailored to each patient's fitness scale (BORG scale) for 6 months. Patients were educated on the importance of exercise. Outcome measures were barriers to exercise, serum phosphorus (P), urea reduction ratio (URR), malnutrition inflammation score, quality of life (QOL using euroqol5) collected at baseline and post intervention. Results. A total of 41 patients completed the study, 61% were males and 90.2%, 53.7% and 14.6% suffered from hypertension, diabetes and cardiovascular disease, respectively. Hyperphosphatemia was prevalent among 75% of the patients with a mean of 5.76 ± 1.66 mg/dl. The mean age was 48 ± 14.37 years, BMI 24.98 ± 6.09 kg/m 2 , URR 71.88 ± 8.52%, and Kt/v 1.32 ± 1.09.The main barrier to exercise was identified to be fatigue on HD days by 58.5% of patients, followed by fear of getting hurt (36.6%). Finally, 80.4% of patients were mildly malnourished and QOL scale was 65.02% ± 18.54. Conclusion. Our study highlighted the widespread of hyperphosphatemia and malnutrition in our sample. The IDE regimen, if proven effective in future studies, could be integrated in the routine practice and may improve patients'outcomes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.